Awarded contract

CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer

Details

Value
GBP 6
Topic
Pharmaceutical products
Published
3 April 2024

Tender description

Proposed NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)<br/>Tender Reference: CM/PHR/22/5686/01<br/> <br/>Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East). Lot 1: CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5) 1 April 2024 to 31 March 2028 -East, SouthEast, London, NOFE

Timeline

  1. Completed: Award date11 March 2024
  2. Completed: Award published3 April 2024
    Current notice

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

6 similar open tenders

See more open tenders related to CM/PHR/22/5686- NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer.

Explore all open tenders

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.